Novartis Ag ADR (NVS)
$107.78
1.65 (1.55%)
NVS Stock Quote Delayed 30 Minutes
GlaxoSmithKline plc (ADR) Stock Jumps on $13 Billion Novartis Deal
GlaxoSmithKline (GSK) stock was up today on news of a $13 billion deal with Novartis (NVS) that it set to close in Summer 2018.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
236,399
Day's Range
$107.59 - $108.34
52-Week Range
$92.19 - $112.48
Dividend & Yield
$3.47 (3.22%)
NVS Stock Predictions, Articles, and Novartis Ag ADR News
Novartis AG (NVS) a Buy on Solid Earnings Visibility
Novartis AG (NYSE:NVS) is classified as a constituent of the 133 company Pharmaceuticals GICS industry group, which is a segment of the 781 company GICS Health Care sector. NVS has a market value of $195.5 billion which is in the top 10% of its industry group. Currently, the stock's Portfolio Grader ranking places it 23 among the 133 companies in this industry group, putting in the top quartile; in the top quartile of the sector with a ranking of 166 among the 781 companies in the sector, and number 1,096 in the nearly 5,000 company Portfolio Grader universe.
Improving Quant Score Metrics Drive Ranking of Novartis AG (NVS) to Buy
The current recommendation of Buy for Novartis AG (NYSE:NVS) has been derived by using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. The shares have been upgraded from a Hold to a Buy in the last week.
Solid Quant Score Metrics Drive Upgrade of Novartis AG (NVS) to Buy
Novartis AG (NYSE:NVS) is ranked as a Buy using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. The shares have been upgraded from a Hold to a Buy in the last week.
Anemic Earnings Growth Hurts Novartis AG (NVS) Rating
The current recommendation of Hold for Novartis AG (NYSE:NVS) has been derived by using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. This represents no change from the previous week and is the same ranking NVS has had from Portfolio Grader for 2 months.
Novartis AG (NVS) Earnings Momentum Hurts Rating
Novartis AG (NYSE:NVS) is a constituent of the 133 company Pharmaceuticals GICS industry group, which is part of the 782 company GICS Health Care sector. NVS has a market value of $200.9 billion which is in the top decile in its industry group. The ranking for NVS by Portfolio Grader places it 45 among the 133 companies in this industry group, giving it an above-average position; in the top half of the sector with a ranking of 297 among the 782 companies in the sector, and number 2,089 in the nearly 5,000 company Portfolio Grader universe.
Novartis AG (NVS) a Hold on Anemic Industry Group Rank
Currently, Novartis AG (NYSE:NVS) has a Hold using the methodology of Louis Navellier for investing and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking NVS has had from Portfolio Grader for 2 months.
Novartis AG’s (NVS) Hold Rating Affirmed
The current recommendation of Hold for Novartis AG (NYSE:NVS) is derived using the Portfolio Grader stock evaluator of Louis Navellier, which incorporates his investing methodology. This represents no change from the previous week and is the same ranking NVS has had from Portfolio Grader for the last month.
Immunize Juno Therapeutics Inc (JUNO) Stock With This Trade
JUNO stock has a lot going for it, but a bullish position looks a good deal better when fully-immunized with an options hedge.
3 Stocks to Watch on Tuesday: Boeing Co (BA), McDonald’s Corporation (MCD) and Novartis AG (ADR) (NVS)
Boeing (BA) has won a dispute with Airbus, McDonald's (MCD) workers strike in the US and UK and Novartis (NVS) names Van Narasimhan its CEO.
Novartis Wins FDA Approval for Groundbreaking Cancer Gene Therapy
Novartis (NVS) has garnered approval from the FDA for its groundbreaking cancer gene therapy, which will cost close to half a million.
United Therapeutics Corporation (UTHR) Shares Soar on Takeover Talk
United Therapeutics (UTHR) shares skyrocketed Friday amidst rumors that the company may be the subject of a takeover by a pharma giant soon.
Novartis AG (ADR) (NVS) Stock Pops on Solid Q2 Earnings
Novartis (NVS) stock got a boost on Tuesday with the release of positive results in its earnings report for the second quarter of 2017.
Teva Pharmaceutical Industries Ltd (ADR) (TEVA): Nibble on Its Dividend and Wait
Teva Pharmaceutical (TEVA) is perhaps the poster child for what can go wrong with an investment. But TEVA stock is cheap and could double in price.
Is Teva Pharmaceutical Industries Ltd (ADR) Stock a Migraine Buy?
Teva's recent migraine drug data, while positive, didn't impress investors. What happened, and should you tussle with TEVA stock?
3 Cheap Biotech Stocks The Big Boys Are Buying (BLRX, OMED, FWP)
Biotechnology is among the most exciting and lucrative sectors for investors, and these 3 biotech stocks stand out...
Valeant Pharmaceuticals Intl Inc (VRX) Stock Is Still Hot Garbage
Valeant Pharmaceuticals flipped to a profit in Q1, and VRX stock is jumping by double digits. But Valeant's long-term issues haven't budged.
Valeant Pharmaceuticals Intl Inc (VRX) Stock Won’t Keep This Rally Up
Valeant earnings are due out Tuesday morning, but it would take a laundry list of good news to sustain the rally in VRX stock.
Here’s How You Can Invest In The World’s Most Innovative Country: Switzerland (EWL)
I've uncovered a data set that show Switzerland as the most innovative country in the world. Here's how to take advantage...
